12/2
08:30 am
pdsb
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
Medium
Report
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
11/25
01:15 pm
pdsb
PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.
11/13
01:39 pm
pdsb
PDS Biotechnology (NASDAQ:PDSB) had its price target raised by analysts at HC Wainwright from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology (NASDAQ:PDSB) had its price target raised by analysts at HC Wainwright from $13.00 to $15.00. They now have a "buy" rating on the stock.
11/13
07:30 am
pdsb
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
High
Report
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
11/12
07:38 pm
pdsb
PDS Biotechnology Q3 2025 Earnings Preview [Seeking Alpha]
High
Report
PDS Biotechnology Q3 2025 Earnings Preview [Seeking Alpha]
11/11
04:29 pm
pdsb
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering [Yahoo! Finance]
Medium
Report
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering [Yahoo! Finance]
11/11
03:31 pm
pdsb
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
High
Report
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
11/10
05:41 pm
pdsb
Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight [Yahoo! Finance]
Medium
Report
Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight [Yahoo! Finance]
11/10
08:30 am
pdsb
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
Medium
Report
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
11/6
08:00 am
pdsb
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
Low
Report
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
10/30
08:00 am
pdsb
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Medium
Report
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/29
08:37 am
pdsb
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
Low
Report
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
9/18
09:04 am
pdsb
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population [Yahoo! Finance]
Low
Report
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population [Yahoo! Finance]
9/18
08:45 am
pdsb
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
Low
Report
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
9/9
07:13 am
pdsb
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures [Forbes]
Low
Report
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures [Forbes]